Gilead And Potential Unforeseen Consequences: Part 1
Many in the patent community, particularly in the pharmaceutical industry, were surprised when the Federal Circuit issued its April opinion in Gilead Sciences Inc. v. Natco Pharma Ltd., No. 2013-1418 (Fed....To view the full article, register now.
Already a subscriber? Click here to view full article